Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
Menu
Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
This program is made possible thanks to an independent educational grant from Ipsen.
Email: IME@springer.com
Your feedback helps us create the most relevant independent programs for your learning needs in the future.